News Releases
September 27, 2024
- New research on alpha-synuclein biomarker assays advance the field regarding quantification and disease differentiation
- Novel human trial finds A-dopamine continuous intracerebroventricular administration safe for Parkinson’s disease
- Anti-inflammatory drug shows potential as disease-modifying therapy for Parkinson’s disease
- Phase 1 clinical trial results support feasibility and safety of administering cell therapy as treatment for people with Parkinson’s disease
- Investigational drug ecopipam may reduce Tourette syndrome severity without exacerbating common mental health conditions
View previous International Congress news releases
September 2023
Featured abstracts:
- Diabetes treatment shows potential as an adjunct therapy for early Parkinson’s disease
- First Tunisian study examining age of onset for biallelic mutations in Huntington’s disease
- Machine learning algorithm applied in classifying tic from non-tic movements
- Machine learnings has potential to assist with diagnosis in Parkinsonian syndromes
- Novel application of machine learning approaches predicts gait dysfunction in Parkinson’s disease
- Safety and efficacy of gene therapy studied in minipigs with Huntington’s disease
- Three months of probiotic therapy shown to reduce motor and nonmotor Parkinson’s disease symptoms
MDS journal news:
- MDS Task Force on Pediatrics publishes recommendations for transitional care for young people with movement disorders
- New data validates an association between trauma-related disorders and the development of Parkinson’s disease in military veterans
September 15, 2022
- Short-term study of Ecopipam Shows Reduction of Tics in Children with Tourette Syndrome
- Regardless of Type, Exercise Improve Quality of Life and Motor Function in People with Parkinson’s Disease
- Climbing Shown to Improve Posture in People with Parkinson’s Disease
- Results from the PPMI Study on an Alpha-Synuclein Seed Amplification Assay
- Use of Continuous Circadian Intracerebroventricular Administration of Anaerobic-Dopamine Reduces Levodopa-Related Complications
- Results from a Phase III Clinical Trial for Subcutaneous Infusion of Foslevodopa/Foscarbidopa
September 14, 2021
- Reduced Quality of Life in People with Parkinson’s Disease of Minority Racial Groups
- Characteristics of Hospitalized COVID-19 Patients with Parkinson’s Disease
- Cost and Availability are Major Barriers in Genetic Testing for Parkinson’s Disease Patients
- The Promising Effects of an α-synuclein Targeted Immunotherapy in Treating Early Parkinson’s Disease
- Reduction of LRRK2 in Human Cerebrospinal Fluid with LRRK2 Small Molecule Inhibitors
- Results from Phase 2 Study of Essential Tremor Therapeutic Shows Improved Upper Limb Tremor
February 9, 2021
• The International Parkinson and Movement Disorder Society (MDS) Continues to Caution Against Unproven Cell-Based Therapies for Parkinson’s Disease
September 11-15, 2020 – Virtual Congress
- Active Immunotherapeutic PD01A for Parkinson’s Disease Phase I Clinical Study
- Early Inflammation as a Potential Predictor of Severe Decline in Nigrostriatal Function
- Multicenter, Deep Brain Stimulation Study Suggests Increased Range of Effective Stimulus Amplitude Using Directional vs. Omnidirectional Leads
- The Association of Loneliness with Quality of Life and Disease Severity in Parkinson’s Disease
September 22-26, 2019 – International Congress – Nice, France
- Lower Serum Biomarkers Found in Early Untreated Parkinson’s Disease
- High Intensity Interval Training May Elevate Serum BDNF Levels in Parkinson’s Disease Patients
- Worldwide Online Survey Aims to Identify a New Comprehensive Approach to Global Collaboration for Parkinson’s Disease
- Patient’s Perception of Non-Motor and Motor Function Successfully Models Parkinson’s Disease Severity
- Safety and Biomarker Effects of Novel Therapeutic for Parkinson’s Disease with GBA Mutations